Cellular Genomics

 

Cellular Genomics is a technology platform that uses known DNA sequence information to design products that can detect genetic changes associated with disease. This platform is especially useful for the detection of cancer since cancer does not occur without genetic change. Some examples of the genetic changes associated with cancer include chromosome aneuploidy, chromosome translocations/rearrangements, deletions, or amplifications. Aneuploidy - a condition where the number of chromosomes in a cell differs from the normal diploid number (two copies of each chromosome, 46 total) by loss or duplication of chromosomes.

Translocation - a condition where part of a chromosome is detached by breakage and then becomes attached to some other chromosome.

Deletion - a condition where a sequence of DNA along a chromosome is removed and the regions on either side become joined together.

Amplification - - refers to the production of additional copies of a chromosomal sequence, which may then be present on the same or a different chromosome.

Direct examination of the genome (all of the DNA within a cell) is a sensitive and powerful means to detect cancer with minimal subjectivity.

Vysis' Cellular Genomics approach to disease management uses two primary technology platforms: Comparative Genomic Hybidization (CGH) and Fluorescence in situ Hybridization (FISH).

The UroVysion Bladder Cancer Kit (UroVysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results from the UroVysion Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.